Xue Bo Zeng
Directeur/Membre du Conseil chez SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.
Profil
Xue Bo Zeng is currently the Director at Chiral Quest (Suzhou) Co., Ltd., Director at Shanghai Model Organisms Center, Inc., Director at Hangzhou Sciwind Biosciences Co., Ltd., Non-Executive Director at Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., Executive Director at IDG Capital, Director at Shandong Bestcomm Pharmaceutical Co., Ltd., Independent Director at CASI Pharmaceuticals, Inc., and Vice President at Hexie Zhuorui Zhuhai Investment Management Co. Ltd.
Mr. Zeng previously worked as Deputy Director at Shenzhen Investment Holdings Co., Ltd.
Mr. Zeng obtained an undergraduate degree from Qinghai Nationalities University in 2009.
Postes actifs de Xue Bo Zeng
| Sociétés | Poste | Début |
|---|---|---|
| SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. | Directeur/Membre du Conseil | 30/07/2022 |
| CASI PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 21/03/2023 |
| SHANGHAI MODEL ORGANISMS CENTER, INC. | Directeur/Membre du Conseil | 01/09/2022 |
| IDG Capital | Directeur/Membre du Conseil | 01/01/2016 |
| Hexie Zhuorui Zhuhai Investment Management Co. Ltd. | Corporate Officer/Principal | 01/11/2020 |
Shandong Bestcomm Pharmaceutical Co., Ltd.
 Shandong Bestcomm Pharmaceutical Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Shandong Bestcomm Pharmaceutical Co., Ltd. is engaged in the research, development and production of domestic pharmaceutical technology. It also offers the development of various new drugs. The company was founded on August 2, 2000 and is headquartered in Jinan, China. | Directeur/Membre du Conseil | 01/12/2017 |
Hangzhou Sciwind Biosciences Co., Ltd.
 Hangzhou Sciwind Biosciences Co., Ltd. BiotechnologyHealth Technology Hangzhou Sciwind Biosciences Co., Ltd. is a biopharmaceutical company based in Hangzhou, China. The Chinese company's product pipeline includes potentially first-in-class and drug candidates, such as the long-acting glp-1 peptide analog ecnoglutide (phase 3), oral glp-1 peptide analog xw004 (phase 1), and oral small molecule glp-1 receptor agonist xw014 (phase 1). Sciwind has developed multiple proprietary technologies, including oral peptide and inhaled protein therapeutic delivery platforms, and identified a series of drug candidates based on these core platform technologies. The company was founded in 2017 by Hai Pan, who has been the CEO since 2017. | Directeur/Membre du Conseil | - |
Chiral Quest (Suzhou) Co., Ltd.
 Chiral Quest (Suzhou) Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Chiral Quest (Suzhou) Co. Ltd. provides drug discovery services. It focuses on the development and manufacture of chiral catalysts, development of synthetic processes, and a technology applications platform. Its products include a, b, and Cyclicb-amino acids; b-hydroxy acids; chiral amines, alcohols, amino alcohols, and pyrrolidines; succinates; and achiral compounds, a-hydroxy acids, and APIs and intermediates. Chiral Quest has one manufacturing site in Jiangxi province, and three overseas offices in USA, Europe & India respectively. The company was founded by Xumu Zhang in 2000 and is headquartered in Suzhou, China. | Directeur/Membre du Conseil | - |
Anciens postes connus de Xue Bo Zeng
| Sociétés | Poste | Fin |
|---|---|---|
Shenzhen Investment Holdings Co., Ltd.
 Shenzhen Investment Holdings Co., Ltd. Financial ConglomeratesFinance Shenzhen Investment Holdings Co., Ltd. operates as a state-owned asset management company. Its business activities include management of properties, capital operation, investment and financing, transportation logistics, manufacturing and trading, and modern service industries. The company was founded on October 13, 2004 and is headquartered in Shenzhen, China. | Corporate Officer/Principal | 01/07/2016 |
Formation de Xue Bo Zeng
| Qinghai Nationalities University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. | Health Technology |
| CASI PHARMACEUTICALS, INC. | Health Technology |
| SHANGHAI MODEL ORGANISMS CENTER, INC. | Commercial Services |
| Entreprise privées | 6 |
|---|---|
| IDG Capital | |
Shenzhen Investment Holdings Co., Ltd.
Shenzhen Investment Holdings Co., Ltd. Financial ConglomeratesFinance Shenzhen Investment Holdings Co., Ltd. operates as a state-owned asset management company. Its business activities include management of properties, capital operation, investment and financing, transportation logistics, manufacturing and trading, and modern service industries. The company was founded on October 13, 2004 and is headquartered in Shenzhen, China. | Finance |
| Hexie Zhuorui Zhuhai Investment Management Co. Ltd. | |
Shandong Bestcomm Pharmaceutical Co., Ltd.
Shandong Bestcomm Pharmaceutical Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Shandong Bestcomm Pharmaceutical Co., Ltd. is engaged in the research, development and production of domestic pharmaceutical technology. It also offers the development of various new drugs. The company was founded on August 2, 2000 and is headquartered in Jinan, China. | Commercial Services |
Hangzhou Sciwind Biosciences Co., Ltd.
Hangzhou Sciwind Biosciences Co., Ltd. BiotechnologyHealth Technology Hangzhou Sciwind Biosciences Co., Ltd. is a biopharmaceutical company based in Hangzhou, China. The Chinese company's product pipeline includes potentially first-in-class and drug candidates, such as the long-acting glp-1 peptide analog ecnoglutide (phase 3), oral glp-1 peptide analog xw004 (phase 1), and oral small molecule glp-1 receptor agonist xw014 (phase 1). Sciwind has developed multiple proprietary technologies, including oral peptide and inhaled protein therapeutic delivery platforms, and identified a series of drug candidates based on these core platform technologies. The company was founded in 2017 by Hai Pan, who has been the CEO since 2017. | Health Technology |
Chiral Quest (Suzhou) Co., Ltd.
Chiral Quest (Suzhou) Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Chiral Quest (Suzhou) Co. Ltd. provides drug discovery services. It focuses on the development and manufacture of chiral catalysts, development of synthetic processes, and a technology applications platform. Its products include a, b, and Cyclicb-amino acids; b-hydroxy acids; chiral amines, alcohols, amino alcohols, and pyrrolidines; succinates; and achiral compounds, a-hydroxy acids, and APIs and intermediates. Chiral Quest has one manufacturing site in Jiangxi province, and three overseas offices in USA, Europe & India respectively. The company was founded by Xumu Zhang in 2000 and is headquartered in Suzhou, China. | Commercial Services |
